TRIAL TO ASSESS CHELATION THERAPY (TACT)

评估螯合疗法的试验 (TACT)

• 批准号: 7375819
• 负责人: PAMELA OUYANG
• 金额: $ 5.22万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375819
• 关键词: TRIAL; ASSESS; CHELATION; THERAPY; TACT

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Coronary heart disease (CHD) is the leading cause of premature morbidity and mortality in the U.S. Currently proven treatments for CHD include lifestyle modification, drugs, and procedures. Despite the availability of these treatments, many patients seek out and receive alternative therapies, including the complementary and alternative medicine (CAM) practice called chelation therapy. Chelation therapy involve IV administration of disodium ethylenediaminetetraacetic acid (EDTA), combined with high dose antioxidant vitamin and mineral supplements. Thus, clinical benefit from chelation therapy, if seen, could be due to EDTA, antioxidants, mineral supplements, or a combination of these. The purpose of this large scale 5-year multi-center trial is: 1) to determine whether chelation or high dose supplements in patients with CHD reduces the incidence of clinical cardiovascular events; 2) to determine whether chelation and high-dose supplements have acceptable safety profiles; 3) To determine whether chelation or high-dose supplements improve the quality of life; 4) To conduct an economic analysis of chelation therapy and high dose supplements.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。冠心病（CHD）是美国过早发病和死亡的主要原因。目前已证实的治疗方法包括改变生活方式、药物和手术。尽管有这些治疗方法，但许多患者寻求并接受替代疗法，包括称为螯合疗法的补充和替代医学（CAM）实践。螯合治疗包括静脉给药乙二胺四乙酸二钠（EDTA），联合大剂量抗氧化维生素和矿物质补充剂。因此，螯合治疗的临床益处，如果看到，可能是由于EDTA，抗氧化剂，矿物质补充剂，或这些的组合。这项为期5年的大规模多中心试验的目的是：1)确定CHD患者的螯合或高剂量补充剂是否能降低临床心血管事件的发生率；2)确定螯合和大剂量补充剂是否具有可接受的安全性；3)确定螯合或大剂量补充剂是否能改善生活质量；4)对螯合疗法和大剂量补剂进行经济分析。